BERKELEY, Calif. — November 24, 2025 — Leads & Copy — Profusa, Inc. (Nasdaq: PFSA) has announced the acceptance of an abstract for a Late Breaking Clinical Trial Update presentation at the upcoming Paris Vascular Insights (PVI) 2025.
The presentation, titled “Monitoring Tissue Oxygen Dynamics with a Novel Implantable Hydrogel Sensor in Patients with Peripheral Arterial Disease (PAD),” will be presented by Peter Schneider, M.D., Professor of Surgery, Division of Vascular & Endovascular Surgery, Department of Surgery, School of Medicine, University of California, San Francisco.
The presentation is scheduled for Saturday, December 13, 2025, from 1 p.m. to 1:40 p.m. CET (Central European Time) at the Carrousel du Louvre in Paris, France.
Profusa’s Chairman and CEO, Ben Hwang, Ph.D., said the Lumee oxygen tissue monitoring technology enables continuous, real-time measurement of tissue oxygen directly within the body. He said it is a first-of-its-kind, disruptive biochemistry monitoring platform designed for use both in the clinic and at home. Hwang added that the company is excited to present an update on its U.S.-based clinical study evaluating the technology with tcpO2 at the late breaking session at PVI, a global vascular community gathering pushing the boundaries of innovation to shape the future of vascular and endovascular surgery.
Profusa, based in Berkeley, Calif., is focused on developing tissue-integrated sensors that detect and continuously transmit actionable, medical-grade data for personal and medical use. The company aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on, utilizing its long-lasting, injectable, and affordable biosensors and intelligent data platform.
The company’s trademarks, “LUMEE”, “PROFUSA” and the PROFUSA logo, are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.
A special note regarding forward-looking statements has been included in the release. These statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements.
Investor and Media Contacts: email: info@coreir.com phone: 1 (212) 655-0924
Source: Profusa
